David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor (Abstract 99).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Issues in Oncology

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida.

Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD

This program is supported by Sandoz Inc.

Leukemia

Julie Vose, MD, MBA

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).

Jun

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Neoadjuvant Sacituzumab Govitecan in MIBC

Thyroid Cancer Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence

Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care

MIBC Intravesical Recombinant BCG and Chemoimmunotherapy

Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC